Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

IGC Pharma (IGC) Depreciation & Amortization (IS) (2016 - 2017)

IGC Pharma has reported Depreciation & Amortization (IS) over the past 5 years, most recently at $4989.0 for Q4 2017.

  • Quarterly Depreciation & Amortization (IS) fell 97.46% to $4989.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$180806.0 through Dec 2017, down 126.89% year-over-year, with the annual reading at $195514.0 for FY2017, 73.17% down from the prior year.
  • Depreciation & Amortization (IS) was $4989.0 for Q4 2017 at IGC Pharma, up from $4344.0 in the prior quarter.
  • Over five years, Depreciation & Amortization (IS) peaked at $323778.0 in Q1 2015 and troughed at -$196103.0 in Q1 2017.
  • The 5-year median for Depreciation & Amortization (IS) is $148352.5 (2013), against an average of $126885.9.
  • Year-over-year, Depreciation & Amortization (IS) soared 37.13% in 2016 and then tumbled 169.85% in 2017.
  • A 5-year view of Depreciation & Amortization (IS) shows it stood at $147708.0 in 2013, then increased by 4.07% to $153725.0 in 2014, then fell by 6.98% to $143000.0 in 2015, then skyrocketed by 37.13% to $196103.0 in 2016, then crashed by 97.46% to $4989.0 in 2017.
  • Per Business Quant, the three most recent readings for IGC's Depreciation & Amortization (IS) are $4989.0 (Q4 2017), $4344.0 (Q3 2017), and $5964.0 (Q2 2017).